Since Walshe (1956) first demonstrated the ability of D-penicillamine to promote the urinary excretion of copper in Wilson's disease, the drug has found a variety of therapeutic applications. With its value in rheumatoid arthritis recently established and studies in chronic active liver disease in progress a renewed interest in the drug has been stimulated. Adverse haematological effects of D-penicillamine, such as thrombocytopenia and neutropenia, occur frequently, and an aplastic anaemia may rarely develop. Selective suppression of the erythroid series has, to our knowledge, not previously been observed. We report here the development of a reversible red cell aplasia in a case of Wilson's disease after 14 years' D-penicillamine therapy. HCl was initiated in a dose of0-9 g daily with gradual resolution of the jaundice and ascites.
By 1965 (aged 15), the patient was asymptomatic, still with prominent Kayser-Fleischer rings and minimal hepatosplenomegaly, but with no features of chronic liver disease or abnormal neurological signs. The haemoglobin level was 14-0 g/dl and conventional liver function tests were normal. Several small opaque gallstones were observed on the abdominal x-ray. Hepatic biopsy showed an inactive cirrhosis with mild fat infiltration and a liver copper concentration of 620 ug/g dry weight (normal < 55 ,ug/g). The urinary excretion of copper was 1500-2000 ,ug/24 h on 0 9 g D-penicillamine daily. Two years later the dose was increased to 1 8 g daily and urinary copper excretion rose to 2300-2800 ,tg/24 h.
The serum caeruloplasmin on this occasion had fallen to 7-2 mg/dl (normal > 20 mg/dl). In 1968, she became pregnant but developed pre-eclamptic toxaemia, and intrauterine death resulted at the 12th week. Although D-penicillamine therapy was maintained throughout the pregnancy no fetal abnormalities were noted. A live male baby was born by Caesarean section in 1970, but in the following yeara further pregnancy was terminated due to toxaemia, and a tubal ligation was performed.
In 1973, after 13 years of chelation therapy, the haemoglobin level was 14-2 g/dl with the red cell indices, total white cell and platelet counts normal. The urinary copper excretion on 1-2 g D-penicilla- Pike and Robinson (1970) with and without addition of Dpenicillamine HCI and D-penicillamine base. Bone marrow was incubated with D-penicillamine for 1-5 h before it was washed and cultured. There was no evidence of in vitro suppression of leucopoiesis by D-penicillamine HCl or D-penicillamine base (table  I) .
The in vitro effect of D-penicillamine on haem synthesis by marrow cells was studied by measuring 59Fe uptake for haem synthesis by marrow erythroblasts (Krantz et al, 1963 Transformation of the patient's lymphocytes, assessed by 3H-thymidine uptake with phytohaemagglutinin (PHA) (Das and Hoffbrand, 1970) , was much less than in a normal control but on addition of D-penicillamine base there was comparable inhibition of 3H-thymidine uptake into the patient's and control lymphocytes. There was no evidence that D-penicillamine base itself caused transformation of the patient's lymphocytes assessed morphologically and by 3H-thymidine uptake (table III) .
Although these in vitro studies did not suggest that the patient's haemopoietic tissues were particularly susceptible to D-penicillamine, the drug was discontinued. Over the ensuing two weeks the haemoglobin concentration stabilized, and during the third week a reticulocyte response became evident (figure). This continued until 10 weeks later when the haemoglobin reached normal levels (13-6 g/dl).
Chelation therapy was discontinued for a total of 14 weeks during which time the patient remained asymptomatic with normal liver function tests and Dixon et al (1972) and was introduced over a four-week period to an optimum dose of 1 6 g daily. This produced an inital urinary copper excretion of 600 ,ug/24 h which subsequently has been maintained at approximately 300 ,ug/24 h. Urinary iron excretion has remained normal on triethylenetetramine dihydrochloride (less than 5
,ug/24 h). Currently the patient is asymptomatic with a normal haemoglobin concentration. The serum IgA level remains low, but transformation of lymphocytes with PHA has reverted to normal.
Discussion
The moderate degrees of thrombocytopenia, neutropenia, and, less frequently, eosinophilia and thrombocytosis which may occur shortly after the initiation of D-penicillamine therapy are rarely severe enough to warrant withdrawal of the drug (Walshe, 1963; Jaffe, 1965; Fawcett et al, 1966; Deiss et al, 1971; Multi-Centre Trial Group, 1973) . Agranulocytosis, which is observed more often in patients with rheumatoid arthritis than Wilson's disease, is usually reversible on cessation of the drug (Payne and Cahill, 1969; Golding et al, 1970; Lievre et al, 1971) , although the outcome may be fatal (Corcos et al, 1964) . Aplastic anaemia is a rare development, usually during the first year of therapy (Bird, 1974; Cramer et al, 1974) and, as with the other haematological effects of D-penicillamine, the reaction appears to be idiosyncratic rather than cytotoxic. Pyridoxine antagonism may be demonstrated in patients on D-penicillamine and pre-existing pyridoxine deficiency may be exacerbated (Swaiman and Milstein, 1970) . However, the antipyridoxine activity of the drug is slight and does not appear to cause clinical signs of deficiency or anaemia. It has been shown that the chelating action of the drug does not influence the serum iron concentration (Walshe and Patston, 1965) , although deficiency may develop as the result of variceal haemorrhage from portal hypertension or following haematuria from glomerulonephritis, which is a rare adverse reaction to D-penicillamine therapy (Sternlieb et al, 1975) . Finally, patients on the drug may develop a lupus-like syndrome with positive tests for antinuclear factor and LE cells. Haematological abnormalities, apart from those due to alimentary blood loss, may occasionally be observed in untreated cases of Wilson's disease. Tntermittent haemolytic episodes may frequently pass unrecognized or precede other manifestations of the disease (McIntyre et al, 1967; Deiss et al, 1970; Iser et al, 1974) , and pancytopenia has also been reported (Heinrich and Kaltenbach, 1965) . The development of anaemia, in this case, appeared to correspond with an increase in the dose of D-penicillamine and a change to the base form of the drug after 14 years' treatment without any adverse reaction on the hydrochloride. Within 10 weeks of this change, the patient was symptomatic and by 16 weeks the haemoglobin had fallen to 4 g/dl. Dpenicillamine induced red cell aplasia was considered in view of the absent reticulocyte response and after investigations had excluded blood loss, haemolysis, a lupus-like reaction, and deficiencies of folate, vitamin B12, and pyridoxine. No other drugs or potential marrow suppressive agents had been taken by the patient.
Pure red cell aplasia has been described following viral infections, complicating haemolytic anaemia and uraemia and with riboflavin deficiency in children with kwashiorkor. Many drugs and chemicals have also been implicated, but, in most cases, withdrawal of the agent resulted in remission (Mitchell, 1973) . Immunological abnormalities have been observed in some cases in association with a thymoma and an IgG autoantibody directed against the patient's erythroblasts (Krantz, 1974) . In the present study, D-penicillamine produced equal inhibition of 59Fe incorporation into erythroblast haem of both the patient and control marrows. The drug did not cause lymphocyte transformation and although a diminished response to PHA was observed during the period of red cell aplasia, the significance of this is uncertain with regard to pathogenesis. The mechanism of drug toxicity thus remains undetermined.
The presence of substantial numbers of red cell precursors in the bone marrow was surprising in view of the low reticulocyte count and severe anaemia. It may be explained by patchy loss of erythropoiesis in the marrow which resulted in a biopsy sampling error. It is also possible that erythroblast development was 
